Cargando…
Direct Medical Cost of Stroke and the Cost-Effectiveness of Direct Oral Anticoagulants in Atrial Fibrillation-Related Stroke: A Cross-Sectional Study
Background: Stroke has significant direct medical costs, and direct oral anticoagulants (DOACs) are better alternatives to warfarin for stroke prevention in atrial fibrillation (AF). This study aimed to determine the direct medical costs of stroke, with emphasis on AF stroke and the cost-effectivene...
Autores principales: | Azahar, Siti Norain, Sulong, Saperi, Wan Zaidi, Wan Asyraf, Muhammad, Norliza, Kamisah, Yusof, Masbah, Norliana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834259/ https://www.ncbi.nlm.nih.gov/pubmed/35162102 http://dx.doi.org/10.3390/ijerph19031078 |
Ejemplares similares
-
Cost-effectiveness of Direct Oral Anticoagulant vs. Warfarin Among Atrial Fibrillation Patients With Intermediate Stroke Risk
por: Choi, Ju Hee, et al.
Publicado: (2022) -
Estimating cost of in-patient medical care for stroke using Casemix data
por: Mohd Nordin, Nor Azlin, et al.
Publicado: (2012) -
Directly Acting Oral Anticoagulants for the Prevention of Stroke in
Atrial Fibrillation in England and Wales: Cost-Effectiveness Model and Value of
Information Analysis
por: Thom, Howard H. Z., et al.
Publicado: (2019) -
Stroke Incidence and Death in Atrial Fibrillation Patients Newly Treated with Direct Oral Anticoagulants
por: Gabet, Amélie, et al.
Publicado: (2021) -
Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review of Cost-Effectiveness Models
por: Limone, Brendan L., et al.
Publicado: (2013)